DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening & Mechanistic Insights

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 bioactive compounds approved by major regulatory agencies, supporting rapid drug repositioning and target identification in translational research (product page). Compounds are provided as pre-dissolved 10 mM DMSO solutions and are stable for 12–24 months depending on storage temperature. The library has been leveraged for screening small molecules such as 5-aminosalicylic acid (5-ASA), revealing new mechanisms in osteoarthritis models (Kim et al., 2024). Mechanistic diversity in the collection spans receptor modulation, enzyme inhibition, and signal pathway regulation. This resource supports high-content screening (HCS), high-throughput screening (HTS), and the systematic exploration of disease-relevant pathways—facilitating precision research in oncology, neurobiology, and immunology.

Biological Rationale

Drug discovery faces high attrition rates. Repurposing approved compounds can dramatically accelerate therapeutic development due to established safety and pharmacokinetics (DiscoveryProbe™ FDA-approved Drug Library: Structured Screening—this article details how expanded screening libraries broaden mechanistic scope beyond the coverage described here). Disease models such as osteoarthritis, cancer, and neurodegenerative disorders often require rapid hypothesis testing with bioactive molecules targeting diverse mechanisms. Curated drug libraries, like the DiscoveryProbe™ FDA-approved Drug Library, enable systematic, high-throughput interrogation of signaling pathways, enzyme activities, and receptor-ligand interactions (From Mechanism to Medicine—this article provides a strategic deployment roadmap, while the current article focuses on experimental benchmarks and integration).

The DiscoveryProbe™ library includes drugs with well-characterized modes of action, such as doxorubicin (topoisomerase II inhibitor), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor). This diversity supports hypothesis-driven and unbiased discovery workflows. High-throughput screening (HTS) with such libraries enables identification of previously unrecognized targets or mechanisms, as exemplified by the discovery of 5-ASA's effect on the OSCAR-PPARγ axis in cartilage (Kim et al., 2024).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library contains compounds categorized by mechanistic class, including:

• Receptor agonists and antagonists: Targeting GPCRs, nuclear hormone receptors, and ion channels.
• Enzyme inhibitors: Inhibiting kinases, phosphatases, proteases, and metabolic enzymes.
• Ion channel modulators: Affecting calcium, sodium, potassium, and chloride channels.
• Signal pathway regulators: Modulating pathways such as PI3K/AKT, MAPK, Wnt, and NF-κB.

All compounds are supplied as pre-dissolved 10 mM solutions in DMSO, aliquoted in 96-well plates, deep-well plates, or 2D barcoded screw-cap tubes for automation compatibility. Stability data confirm at least 12 months at -20°C and 24 months at -80°C. The library enables both cell-based and biochemical assays, facilitating screening for hit identification, pathway modulation, or drug repositioning (Redefining Drug Discovery—the prior article explores strategic implications; here, detailed mechanisms and workflow settings are addressed).

Evidence & Benchmarks

• Screening 3,287 compounds from an FDA-approved library identified 5-aminosalicylic acid (5-ASA) as an inhibitor of OSCAR-collagen binding in chondrocytes (Kim et al., 2024).
• 5-ASA intra-articular injection (dose: 2.5 mg/kg, weekly for 3 weeks) ameliorated osteoarthritis in the DMM mouse model, with significant cartilage thickness improvement compared to controls (Kim et al., 2024).
• DiscoveryProbe™ library compounds are validated as 10 mM DMSO solutions, with stability maintained for 12 months at -20°C and 24 months at -80°C (ApexBio product documentation).
• HTS and HCS with this library have enabled pharmacological target identification in oncology, neurodegeneration, and infectious disease models (ApexBio use cases).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for:

• High-throughput phenotypic screening in cell-based and biochemical assays.
• Identification of drugs suitable for repositioning in new disease contexts.
• Rapid validation of pharmacological targets in preclinical models.
• Exploration of diverse mechanisms, including receptor, enzyme, and pathway modulation.
• Screening for disease-modifying activity in models of cancer, neurodegeneration, and inflammatory disease.

Common Pitfalls or Misconceptions

• The library does not include investigational or non-approved compounds; it is limited to molecules with regulatory approval or pharmacopeia listing.
• Compounds are not guaranteed to be active in all assay systems—biological context and readout sensitivity are critical.
• Repositioning hits require further validation in secondary and in vivo models before clinical translation.
• Compound concentration (10 mM stock) may require dilution optimization for specific cell types or assay formats.
• Shipping conditions (blue ice, room temperature) do not substitute for recommended long-term storage (<-20°C or -80°C) to maintain stability.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is formatted for direct integration into automated HTS and HCS platforms. Compounds are pre-dissolved in DMSO at 10 mM and can be dispensed into 96-well or deep-well assay plates using robotic liquid handlers. Each compound is tracked via 2D barcoding for sample integrity and traceability. The library supports parallel screening across multiple disease models and readouts, including proliferation, reporter assays, and pathway-specific markers.

For example, in the osteoarthritis study, small molecules were screened for their ability to block OSCAR-collagen binding using an in vitro binding assay, followed by in vivo validation in mouse models (Kim et al., 2024). The L1021 kit's standardized format minimizes variability and supports rapid hit triage. Data from these screens can be integrated with transcriptomic, proteomic, or phenotypic data to prioritize candidate compounds.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library provides a rigorously curated, automation-ready resource for high-content and high-throughput screening in drug discovery. Its application has enabled the identification of novel drug mechanisms, such as the inhibition of OSCAR-collagen interaction by 5-ASA in osteoarthritis (Kim et al., 2024). By streamlining target validation and drug repositioning, this collection accelerates preclinical research in oncology, neurodegeneration, and beyond. For further details or to obtain the L1021 kit, visit the DiscoveryProbe™ FDA-approved Drug Library product page. This article expands upon the strategic and mechanistic context provided in previous articles, adding structured, evidence-focused benchmarks for practical integration.